Literature DB >> 21609230

Current Clinical Trials in Dry AMD and the Definition of Appropriate Clinical Outcome Measures.

Zohar Yehoshua1, Philip J Rosenfeld, Thomas A Albini.   

Abstract

Currently, there is no proven drug treatment for dry age-related macular degeneration (AMD). Several different treatment strategies are being investigated, including complement inhibition, neuroprotection, and visual cycle inhibitors, and novel clinical trial endpoints are being explored. Studies have identified genetic predispositions for dry AMD associated with complement dysfunction. Consequently, complement-based therapeutic treatment modalities are promising.

Entities:  

Mesh：

Year:  2011        PMID： 21609230     DOI： 10.3109/08820538.2011.577132

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN： 0882-0538            Impact factor:   1.975


  24 in total

1.  A false color fusion strategy for drusen and geographic atrophy visualization in optical coherence tomography images.

Authors:  Qiang Chen; Theodore Leng; Sijie Niu; Jiajia Shi; Luis de Sisternes; Daniel L Rubin
Journal:  Retina       Date:  2014-12       Impact factor: 4.256

2.  Elevated membrane attack complex in human choroid with high risk complement factor H genotypes.

Authors:  Robert F Mullins; Aaron D Dewald; Luan M Streb; Kai Wang; Markus H Kuehn; Edwin M Stone
Journal:  Exp Eye Res       Date:  2011-06-26       Impact factor: 3.467

3.  Inflammatory mediators induced by amyloid-beta in the retina and RPE in vivo: implications for inflammasome activation in age-related macular degeneration.

Authors:  Ruozhou Tom Liu; Jiangyuan Gao; Sijia Cao; Navroop Sandhu; Jing Z Cui; Chai Lin Chou; Edward Fang; Joanne A Matsubara
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-01       Impact factor: 4.799

4.  Optical coherence tomography-based correlation between choroidal thickness and drusen load in dry age-related macular degeneration.

Authors:  Ashley Ko; Sijia Cao; Kaivon Pakzad-Vaezi; Penelope M Brasher; Andrew B Merkur; David A Albiani; Andrew W Kirker; Jing Cui; Joanne Matsubara; Farzin Forooghian
Journal:  Retina       Date:  2013-05       Impact factor: 4.256

5.  Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.

Authors:  Tiarnan D Keenan; Elvira Agrón; Amitha Domalpally; Traci E Clemons; Freekje van Asten; Wai T Wong; Ronald G Danis; SriniVas Sadda; Philip J Rosenfeld; Michael L Klein; Rinki Ratnapriya; Anand Swaroop; Frederick L Ferris; Emily Y Chew
Journal:  Ophthalmology       Date:  2018-07-27       Impact factor: 12.079

6.  Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.

Authors:  Wai T Wong; Samuel Dresner; Farzin Forooghian; Tanya Glaser; Lauren Doss; Mei Zhou; Denise Cunningham; Katherine Shimel; Molly Harrington; Keri Hammel; Catherine A Cukras; Frederick L Ferris; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-26       Impact factor: 4.799

7.  Retinal pigment epithelial cell death by the alternative complement cascade: role of membrane regulatory proteins, calcium, PKC, and oxidative stress.

Authors:  Ping Yang; Peter Baciu; Brittany C Parker Kerrigan; Menna Etheridge; Eric Sung; Brett A Toimil; Jacob E Berchuck; Glenn J Jaffe
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-06       Impact factor: 4.799

8.  Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.

Authors:  Zohar Yehoshua; Carlos Alexandre de Amorim Garcia Filho; Renata Portella Nunes; Giovanni Gregori; Fernando M Penha; Andrew A Moshfeghi; Kang Zhang; Srinivas Sadda; William Feuer; Philip J Rosenfeld
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

9.  A novel role of complement in retinal degeneration.

Authors:  Minzhong Yu; Weilin Zou; Neal S Peachey; Thomas M McIntyre; Jinbo Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-19       Impact factor: 4.799

Review 10.  Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.

Authors:  Daniel Ricklin
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.